在肉瘤中高剂量ifosfamide的长期益处取决于持续的先前控制和及时干预:机器学习分析分析
Michael Hoberger1, Romy L Zuber1, Anton Burkhard-Meier1,2
1Department of Medicine III, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
Journal of cancer research and clinical oncology
|January 8, 2026
概括
高剂量伊福斯法米德 (HD-IFO) 提供了先进的骨和软组织肉瘤的持久疾病控制. 长期益处的关键预测因素包括先前的瘤控制和疾病进展前的干预.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 高剂量伊福斯法米德 (HD-IFO) 是一种成熟的治疗方法,用于晚期骨和软组织肉瘤.
- 预测HD-IFO治疗对患者长期益处的预测因素尚未确定.
研究的目的:
- 评估临床结果,并确定治疗HD-IFO的肉瘤患者的预后因素.
- 利用机器学习辅助建模来分析治疗有效性.
主要方法:
- 对26名接受HD-IFO治疗的肉瘤患者 (每周期≥12g/m2) 的回顾性分析.
- 使用Kaplan-Meier和日志等级测试分析的无进展生存率 (PFS) 和总生存率 (OS).
- 通过LASSO逻辑回归和多变量分析确定的预后因素.
主要成果:
- 中位数PFS为6.6个月,中位数OS为24.7个月.
- 实现部分反应或稳定疾病的患者的生存寿命明显长于疾病进展的患者.
- 在进展前的干预和先前的瘤控制 (≥12个月) 独立预测的OS>24个月.
结论:
- 在精选的肉瘤患者中,HD-IFO可以提供持久的疾病控制.
- 持续的先前瘤控制和早期干预对于HD-IFO治疗的长期结果至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


